Impact of COVID-19 on the management and outcomes of ureteric stones in

the UK: a multicentre retrospective study

Matthew H V Byrne^{1,2}, Fanourios Georgiades^{3,4}, Alexander Light⁵, Catherine E Lovegrove^{1,2}, Catherine Dominic⁶, Josephine Rahman⁷, Senthooran Kathiravelupillai⁸, Tobias Klatte⁹, Kasra Saeb-Parsy⁴. Rajeev Kumar¹, Sarah Howles^{1,2}, Grant D Stewart^{3,4}, Ben Turney^{1,2}, Oliver Wiseman⁴ on behalf of the COVID Stones Collaborative*

Affiliations:

Corresponding author

Name: Matthew Byrne

Email address: matthew.byrne@nds.ox.ac.uk

Full Institution address: Oxford University Hospitals NHS Foundation Trust, UK

Institution post code: OX3 7LE

Twitter: @mhvbyrne

Authorship: MHVB and FG were responsible for conceptualisation. All authors were responsible for writing the first draft and revisions. AL, CD, JR, RK, and Members of the COVID Stone Collaborative were responsible for data collection. MHVB was responsible for data analysis. SH, GDS, BT, and OW were responsible for supervision. BT and OW are the guarantors. All authors have seen and approved the final version.

Sources of support: None

Conflicts of interests: GDS - educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and CMR Surgical; Speaker fees from Pfizer; Trustee The Urology Foundation and Kidney Cancer UK; Travel expenses from Pfizer. OJW: consulting fees: Boston Scientific, EMS, Coloplast, Ambu, Astellas. Speaker fees: Education Boston Scientific, EMS, Coloplast, Ambu. Research grants Coloplast, EMSI; Trustee BAUS, Treasurer BAUS. BT: consulting fees: Boston Scientific; Speaker fees: Boston Scientific, Devicare, BJUI (subeditor); Data safety monitoring / advisory board: Boston Scientific.

¹Nuffield Department of Surgical Sciences, University of Oxford, UK

²Oxford University Hospitals NHS Foundation Trust, UK

³Department of Surgery, University of Cambridge, UK

⁴Cambridge University Hospitals NHS Foundation Trust, UK

⁵Department of Surgery and Cancer, Imperial College London, UK

⁶Barts and the London School of Medicine, Queen Mary University of London, UK ⁷University of Bristol, UK

⁸School of Clinical Medicine, University of Cambridge, UK

⁹Department of Urology, Charité - Universitätsmedizin Berlin, Germany

^{*}Collaborating authors are listed in Appendix A

Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval: We followed NHS Health Research Authority guidance and the study did not require ethical approval. Each participating site obtained local audit approval.

Acknowledgements: None

Study type: Retrospective cohort study

Running Title: COVID Stones study

Key words: Urolithiasis, ureteric stone, ureteral stone, COVID-19, patient outcomes, management, conservative management, spontaneous stone passage, ESWL, ureteroscopy, nephrostomy

Number of figures: 1 (+ 0 supplementary) **Number of tables**: 3 (+ 1 supplementary)

Word count: 2079

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

ABSTRACT Objectives: To determine if management of ureteric stones in the United Kingdom changed during the COVID-19 pandemic and whether this affected patient outcomes. Patients and methods: We conducted a multicentre retrospective study of adults with CT-proven ureteric stone disease at 39 UK hospitals during a pre-pandemic period (23/3/19 to 22/6/19) and a period during the pandemic (the 3-month period after the first SARS-CoV-2 case at individual sites). The primary outcome was success of primary treatment modality, defined as no further treatment required for the index ureteric stone. Our study protocol was published prior to data collection. **Results:** A total of 3735 patients were included (pre-pandemic=1956 patients; pandemic=1779 patients). Stone size was similar between groups (p>0.05). During the pandemic, patients had lower hospital admission rates (pre-pandemic=54.0% vs pandemic=46.5%, p<0.001), shorter length of stay (mean=4.1 vs. 3.3 days, p=0.02), and higher rates of use of medical expulsive therapy (17.4% vs. 25.4%, p<0.001). In patients who received interventional management (pre-pandemic n=787 vs. pandemic n=685), rates of ESWL (22.7% vs. 34.1%, p<0.001) and nephrostomy were higher (7.1% vs. 10.5%, p=0.03); and rates of ureteroscopy (57.2% vs. 47.5%, p<0.001), stent insertion (68.4% vs. 54.6%, p<0.001), and general anaesthetic (92.2% vs. 76.2%, p<0.001) were lower. There was no difference in success of primary treatment modality between patient

cohorts (pre-pandemic=73.8% vs. pandemic=76.1%, P=0.11), nor when patients

were stratified by treatment modality or stone size. Rates of operative complications, 30-day mortality, and readmission and renal function at 6 months did not differ between the data collection periods.

Conclusions: During the COVID-19 pandemic, there were lower admission rates and fewer invasive procedures performed. Despite this, there were no differences in treatment success or outcomes. Our findings indicate that clinicians can safely adopt management strategies developed during the pandemic to treat more patients conservatively and in the community.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

INTRODUCTION Nephrolithiasis is a major clinical and economic health challenge. Up to 20% of men and 10% of women are affected by stone disease 1,2. It is responsible for over 85,000 hospital episodes in the UK and costs the UK National Health Service (NHS) an estimated £190-324 million per year ³. The management of ureteric stones can be conservative, as most stones smaller than 5mm pass spontaneously ⁴. However, interventions such as extracorporeal shockwave lithotripsy (ESWL) or ureteroscopic (URS) laser lithotripsy may be required. Untreated stone disease can result in refractory pain, sepsis, renal failure, and death 5. The UK National Institute for Health and Care Excellence (NICE) guidelines published in 2019 recommend that adults with ureteric stones measuring less than 10mm should be treated with ESWL and URS is recommended as a second line alternative. For ureteric stones measuring between 10 and 20mm, URS should be offered as first line treatment, and ESWL can be considered if local facilities will allow stone clearance to be achieved within 4 weeks 6. In March 2020, COVID-19 was declared a pandemic by the World Health Organisation (WHO), and measures were introduced across the world to mitigate the spread of infection ⁷. There was worldwide disruption to healthcare provision, including increased pressures on healthcare services and the cancellation of elective procedures 8. The multicentre, international COVIDSurg study demonstrated that perioperative infection with the SARS-CoV-2 virus was associated with an unadjusted 30-day mortality of 23.8% 9. In light of this, and as a result of reduced access to operating theatres, recommendations were made to favour non-operative

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

management strategies 8,10-12. Furthermore, during the peak of the pandemic in the UK, non-COVID-19 related Emergency Department attendances fell dramatically as patients delayed or avoided presentation to hospital due to fear of infection ¹³. The existing body of literature around COVID-19 and endourology discusses alterations required of clinical care to accommodate the widespread disruption to healthcare services due to COVID-19. However, these articles were written at the start of the COVID-19 pandemic and do not discuss whether these suggested changes to treatment algorithms manifested during the pandemic or what their impact on outcomes were ^{11,12,14}. We hypothesised that during COVID-19 there were delays in patient presentation resulting in higher rates of AKI and sepsis and that non-invasive management options such as observation, ESWL, and alternatives to general anaesthesia were used more frequently, resulting in higher rates of failed index management and subsequent change in treatment modality and/or re-presentation to hospital. We sought to test this hypothesis by undertaking a multicentre, retrospective study to determine how management of ureteric stones changed during the COVID-19 pandemic in the United Kingdom and define how changes in management affected patient outcomes.

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

METHODS Study design We conducted a multicentre, retrospective cohort study of the management and outcomes of patients presenting with ureteric stones before and during the COVID-19 pandemic at 39 hospitals in the United Kingdom. Our protocol was published prior to data collection ¹⁵. We followed principles of the trainee-led collaborative research model ¹⁶, coordinated by the COVID Stones Collaborative; and the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines ¹⁷ (Appendix B). NHS Health Research Authority guidance was followed, and each participating site obtained local audit approval. Patients aged ≥18 years with ureteric stone disease confirmed on contrast or noncontrast computed tomography (CT) imaging were identified via retrospective review of all abdominal CT scans undertaken during relevant data collection periods. Patients with non-ureteric stone disease were excluded. **Data collection** Data was collected during two time periods: a pre-pandemic period from 23/3/19 to 22/6/19; and a period during the pandemic, which was defined as the 3-month period after the first SARS-CoV-2 case at each individual site. This time point was approximately equivalent to the start of the first UK lockdown due to Covid-19 on 23/3/20. Data was collected by local collaborators, and entered and stored on the Research Electronic Data Capture (REDCap) server managed and hosted by the

104

105

106

107

108

109

110

111

112

113

114

115

116

117

University of Oxford, UK ^{18,19}. Data collected included demographics, management and outcomes at 6 months follow-up. **Outcomes** Our primary objective was to assess success of primary treatment modality, defined as no additional treatment required for the index ureteric stone. Our secondary objectives were to assess rates of non-operative management, ESWL, stent insertion, ureteroscopy, and nephrostomy insertion; type of anaesthesia for operative management options; operative complications; hospital admission and length of stay; 30-day and 6-month mortality; readmission, and impact of stone on renal function. Statistical analysis Statistical analysis was performed using R (version 4.1.0) 20. Patients in the prepandemic cohort were compared to patients in the pandemic cohort. Two-sided unpaired t-tests, and Chi-squared tests were used to analyse the data. Data is presented as mean ± standard deviation (SD) or as raw number and percentage. A p-value <0.05 was deemed significant.

RESULTS

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

Demographics Data were collected from a total of 3735 patients from 39 centres. In the prepandemic period data were entered for 1956 patients, and in pandemic period data was entered for 1779 patients. Baseline patient characteristics were broadly similar (Table 1). Although, there was a significant difference in age between cohorts, the median age group for both cohorts was 50-59 years. Stone site and size were similar between cohorts (Table 1). Unexpectedly, patients from the pre-pandemic cohort were reported to have significantly higher rates of active infection and acute kidney injury on admission, and fever at any point during index admission. However, mean C-reactive protein, white cell count, positive microbiology cultures (urine or blood), and creatinine were not significantly different (Table 1). Management Overall, patients in the pandemic period had significantly lower rates of admission to hospital (pre-pandemic 54.0% vs. pandemic 46.5%, p<0.001) and shorter length of stay in hospital (mean length of stay in days, pre-pandemic=4.1 (SD=8.0) vs. pandemic=3.3 (SD=5.9), p=0.02) compared to the pre-pandemic period. The use of alpha blockers was significantly higher during the pandemic (pre-pandemic=17.4% vs. pandemic=25.4%, p<0.001). Despite the higher rates of active infection and fever, antibiotic usage was similar between cohorts (Table 2).

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

Interventional management There were no differences in rates of interventional management between the cohorts (pre-pandemic, n=787 [40.2%] vs. pandemic, n=685 [38.5%], p=0.30), or ASA grade (p=0.50) and WHO/ECOG Performance status (p=0.21) in patients who received operative management (Table S1). However, there were significantly higher rates of ESWL and nephrostomy insertion, and significantly lower rates of general anaesthetic, ureteroscopy and stent insertion during the pandemic compared to prepandemic (Figure 1, Table 2). During the pandemic, planned interventions were delayed due to COVID-19 status in 63 out of 1580 patients (4.0%). **Outcomes** 30-day outcomes The 30-day operative complication rate among those who received operative management was similar between the pre-pandemic and pandemic cohort (Table 2). as was the 30-day mortality rate (any cause) across the whole of each cohort (prepandemic=8 of 1793 [0.5%] vs. pandemic=9 of 1640 [0.6%], p=0.85). 6-month outcomes The success rate of primary treatment (i.e. no further treatment required for the index stone after primary treatment modality) was similar between cohorts (prepandemic=73.8% vs. pandemic=76.1%, p=0.11). There was no significant difference in success of primary treatment modality when stratified by treatment modality or stone size.

In patients who did require further intervention, the rates of ESWL, ureteroscopy, retrograde stent insertion, and nephrostomy were similar between each cohort (Table 3).

The mean number of unplanned admissions (pre-pandemic=0.17 (SD=0.52) vs. pandemic=0.18 (SD=0.50), p=0.83), mean creatinine (pre-pandemic=87.3 (SD=36.9) vs. pandemic=89.4 (SD=51.9) µmol/L, p=0.31), and chronic kidney disease stage 1 to 5 (pre-pandemic=17.1% vs. pandemic=17.9%, p=0.99) were similar between cohorts. There was a higher mortality rate in the pre-pandemic cohort group (pre-pandemic=40 of 1830 [2.1%] vs. pandemic=18 of 1700 [1.1%], p=0.01).

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

DISCUSSION In response to the COVID-19 pandemic, strategies to prioritise and triage patients with urological pathology were developed ¹². These included conservative treatment whenever possible ¹², and use of local-anaesthesia to minimise ventilator use and reduce risk of COVID-19 exposure 11,12,14. If operative management was deemed necessary, recommendations were made to select patients according to surgical priority using patient factors (symptoms, comorbidities, and renal tract abnormalities) and stone factors (obstruction, infection, and conservative management failure) 11,12. In cases where there was an infected, obstructed system, multiple sources recommended insertion of a ureteric stent under local anaesthetic as first line treatment, with nephrostomy as second line option ^{12,14}. In this study, we demonstrate that the management of ureteric stones changed across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We also found that rates of nephrostomy were higher, despite lower rates of AKI and active infection. Other studies have reported a decrease in urological presentations during the COVID-19 pandemic ^{21–24} We therefore predicted that during the pandemic patients with ureteric colic would have delayed presenting to hospital and therefore have been a more unwell cohort. However, in our data, rates of AKI and active infection were lower in the pandemic patient cohort suggesting that these patients did not

delay their presentation long enough to impact their clinical condition. These findings

contrast with other urolithiasis datasets. Castellani et al. compared ureteric stone

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

disease outcomes of 298 patients prior to the pandemic with 218 patients during the pandemic, reporting reduced admissions and higher rates of infected-obstructed systems, hospitalisation, and intervention during the COVID-19 pandemic²⁵. Furthermore, Flammia et al. found that serum creatinine was significantly higher in 36 patients with urinary stone emergencies during the pandemic compared to 44 patients with urinary stone emergencies prior to the pandemic, which the authors posited was due to delayed presentation ²⁶. Similarly, Gul et al. demonstrated an increase in creatinine, white cell count, hospital admissions, antibiotic treatment, and emergency nephrostomy insertion in 35 patients with urolithiasis during the pandemic compared to 114 patients with urolithiasis prior to the pandemic ²⁷. Our findings are consistent with those reported by Anderson et al. and Nourian et al. who identified no difference in markers of infection or AKI between pre-pandemic and post-pandemic cohorts of patients presenting with urolithiasis ^{28, 29}. Our study represents the largest cohort to date investigating ureteric stone outcomes during the pandemic, has a multicentre design and had a pre-defined protocol. Thus, we predict our findings are representative of true outcomes in the UK during the COVID-19 pandemic. Steinberg et al. suggested that we can use the COVID-19 pandemic as an opportunity to reassess ureteric stone management strategies, and establish whether conservative management strategies have been under-used ³⁰. Our study is the first to evaluate the impact of changes in the management of ureteric stones during the COVID-19 pandemic on patient outcomes at 6 month follow up ^{26,28,29,31,32}. We demonstrate that increased use of conservative management strategies did not

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

have a detrimental effect on primary treatment success or patient outcomes at 6month follow up. Our data supports increased use of less-invasive options recommended by NICE guidance including watchful waiting with medical expulsive therapy and ESWL as first line – there was an approximately 10% shift from URS to ESWL during the pandemic with non-inferior outcomes. Our data also support a reduction in admission rates and earlier discharge. It is unclear whether these changes will revert once the pandemic stabilises and patient backlog is tackled or if practice will change permanently. Evidence such as this should drive a more permanent change to less-invasive management, as the change in practice during the pandemic has shown that this is safe and as effective. This study is the first of its kind to be conducted across multiple sites with 6-month follow-up. However, the study is limited by its retrospective design, and missing data. Our study was conducted across 39 centres and the number of cases entered by each centre varied considerably. This may be due to differences in local patient populations, however, it may be that not all patients within each time period were captured. This increases the risk of selection bias within our study and therefore no comment can be made on whether there was a change in the number of presentations with ureteric stone disease during each time period.

CONCLUSIONS

As a result of the COVID-19 pandemic patients in the UK with ureteric stones were less likely to be treated invasively and more likely to be managed without admission. However, this change in practice did not result in inferior outcomes for patients. The pandemic has given the urological community an opportunity to re-evaluate management of ureteric stones; our findings indicate that a greater proportion of ureteric stones can be managed safely and effectively with non-invasive ambulatory options.

REFERENCES

- 250 1. Heers H, Turney BW. Trends in urological stone disease: a 5-year update of
- 251 hospital episode statistics. *BJU Int.* 2016;118(5):785-789.
- 252 doi:10.1111/bju.13520
- 253 2. Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of Kidney Stones in
- 254 the United States. Eur Urol. 2012;62(1):160-165.
- 255 doi:10.1016/j.eururo.2012.03.052
- 256 3. Geraghty RM, Cook P, Walker V, Somani BK. Evaluation of the economic
- burden of kidney stone disease in the UK: a retrospective cohort study with a
- 258 mean follow-up of 19 years. *BJU Int.* 2020;125(4):586-594.
- 259 doi:10.1111/bju.14991
- 260 4. Shah TT, Gao C, Peters M, et al. Factors associated with spontaneous stone
- passage in a contemporary cohort of patients presenting with acute ureteric
- 262 colic: results from the Multi-centre cohort study evaluating the role of
- 263 Inflammatory Markers In patients presenting with acute ureteric. *BJU Int.*
- 264 2019;124(3):504-513. doi:10.1111/bju.14777
- 265 5. PEARLE MS, PIERCE HL, MILLER GL, et al. OPTIMAL METHOD OF
- 266 URGENT DECOMPRESSION OF THE COLLECTING SYSTEM FOR
- 267 OBSTRUCTION AND INFECTION DUE TO URETERAL CALCULI. J Urol.
- 268 1998;160(4):1260-1264. doi:10.1016/S0022-5347(01)62511-4
- 269 6. NICE guideline NG118: Renal and ureteric stones: Assessment and
- 270 management.
- 7. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed.
- 272 2020;91(1):157-160. doi:10.23750/abm.v91i1.9397
- 273 8. COVIDSurg Collaborative . Elective surgery cancellations due to the COVID-

274 19 pandemic: global predictive modelling to inform surgical recovery plans. Br 275 J Surg. June 2020. doi:10.1002/bjs.11746 276 Nepogodiev D, Bhangu A, Glasbey JC, et al. Mortality and pulmonary 9. 277 complications in patients undergoing surgery with perioperative SARS-CoV-2 278 infection: an international cohort study. Lancet. 2020;396(10243):27-38. 279 doi:10.1016/S0140-6736(20)31182-X 280 10. Royal College of Surgeons of England. Updated Inter-collegiate General 281 Surgery Guidance on COVID-19. London: Royal College of Surgeons of 282 England. 283 11. Metzler IS, Sorensen MD, Sweet RM, Harper JD. Stone Care Triage During 284 COVID-19 at the University of Washington. J Endourol. 2020;34(5):539-540. 285 doi:10.1089/end.2020.29080.ism 286 12. Proietti S, Gaboardi F, Giusti G. Endourological Stone Management in the Era 287 of the COVID-19. Eur Urol. 2020;78(2):131-133. 288 doi:10.1016/j.eururo.2020.03.042 289 Thornton J. Covid-19: A&:E visits in England fall by 25% in week after 13. 290 lockdown. BMJ. April 2020:m1401. doi:10.1136/bmj.m1401 291 14. Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of 292 Urologic Surgeries During the COVID-19 Pandemic. Eur Urol. 2020;77(6):663-293 666. doi:10.1016/i.eururo.2020.03.027 294 15. Georgiades F, Byrne MH, Lovegrove CE, et al. The COVID Stones 295 Collaborative: How has the Management of Ureteric Stones Changed During 296 and After the COVID-19 Pandemic? Rationale and Study Protocol. J 297 Endoluminal Endourol. 2020;3(3):e22-e28. doi:10.22374/JELEU.V3I3.96 298 16. Blencowe N, Glasbey J, Heywood N, et al. Recognising contributions to work

299 in research collaboratives: Guidelines for standardising reporting of authorship 300 in collaborative research. *Int J Surg.* 2018;52:355-360. 301 doi:10.1016/J.IJSU.2017.12.019 302 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke 17. 303 JP. The Strengthening the Reporting of Observational Studies in Epidemiology 304 (STROBE) statement: guidelines for reporting observational studies. Lancet. 305 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X 306 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research 307 electronic data capture (REDCap)—A metadata-driven methodology and 308 workflow process for providing translational research informatics support. J 309 Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010 310 19. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an 311 international community of software platform partners. J Biomed Inform. 312 2019;95:103208. doi:10.1016/j.jbi.2019.103208 313 20. R Core Team. R: A language and environment for statistical computing. 2017. 314 https://www.r-project.org/. 315 Madanelo M, Ferreira C, Nunes-Carneiro D, et al. The impact of the 21. 316 coronavirus disease 2019 pandemic on the utilisation of emergency urological 317 services. BJU Int. 2020;126(2):256-258. doi:10.1111/BJU.15109 318 22. Motterle G, Morlacco A, lafrate M, et al. The impact of COVID-19 pandemic on 319 urological emergencies: a single-center experience. World J Urol. 2021;39(6). 320 doi:10.1007/S00345-020-03264-2 321 23. Porreca A, Colicchia M, D'Agostino D, et al. Urology in the Time of 322 Coronavirus: Reduced Access to Urgent and Emergent Urological Care during 323 the Coronavirus Disease 2019 Outbreak in Italy. Urol Int. 2020;104(7-8):631-

324		636. doi:10.1159/000508512
325	24.	Korkes F, Smaidi K, Salles MP, Neto ACL, Heilberg IP, Glina S. COVID-19:
326		The impact on urolithiasis treatment in Brazil. Int Braz J Urol. 2022;48(1):101-
327		109. doi:10.1590/S1677-5538.IBJU.2021.0405
328	25.	Castellani D, Ragonese M, Di Rosa M, et al. An Italian multicenter analysis of
329		emergency admissions and treatment of upper tract urolithiasis during the
330		lockdown and reopening phases of the COVID-19 pandemic: Are we ready for
331		a second wave of the outbreak? Int J Urol. 2021;28(9):950.
332		doi:10.1111/IJU.14612
333	26.	Flammia S, Salciccia S, Tufano A, Busetto GM, Ricciuti GP, Sciarra A. How
334		urinary stone emergencies changed in the time of COVID-19? Urolithiasis.
335		2020;48(5):467-469. doi:10.1007/s00240-020-01198-3
336	27.	Gul M, Kaynar M, Yildiz M, et al. The Increased Risk of Complicated Ureteral
337		Stones in the Era of COVID-19 Pandemic. <i>J Endourol</i> . 2020;34(8):882-886.
338		doi:10.1089/end.2020.0658
339	28.	Anderson S, McNicholas D, Murphy C, et al. The impact of COVID-19 on acute
340		urinary stone presentations: a single-centre experience. Ir J Med Sci.
341		2022;191(1):45-49. doi:10.1007/S11845-021-02562-X
342	29.	Nourian A, Uppaluri C, Chen M, Ghiraldi EM, Friedlander JI. Comparison of
343		Management and Outcomes of Symptomatic Urolithiasis During the COVID-19
344		Pandemic to a Comparative Cohort. <i>Urology</i> . 2022.
345		doi:10.1016/J.UROLOGY.2022.01.019
346	30.	Steinberg RL, Johnson BA, Antonelli J, Pearle MS. Urolithiasis in the COVID
347		Era: An Opportunity to Reassess Management Strategies. Eur Urol.
348		2020;78(6):777. doi:10.1016/J.EURURO.2020.07.019

349 Liu Z, Man L. Impacts of the COVID-19 outbreak on visits and treatments for 31. 350 patients with ureteral stones in a general hospital emergency department. Urol 351 J. 2021;88(3):232-236. doi:10.1177/0391560320985659 352 32. Gökce Mİ, Yin S, Sönmez MG, et al. How does the COVID-19 pandemic affect 353 the preoperative evaluation and anesthesia applied for urinary stones? EULIS 354 eCORE-IAU multicenter collaborative cohort study. Urolithiasis. 355 2020;48(4):345-351. doi:10.1007/s00240-020-01193-8 356

FIGURE CAPTIONS

357

358




Figure 1: Change in interventional management during the pandemic

TABLE CAPTIONS

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	p- value
Age group			0.02
18-19 years	11 (0.6%)	17 (1.0%)	
20-29 years	198 (10.1%)	164 (9.2%)	
30-39 years	340 (17.4%)	346 (19.4%)	
40-49 years	361 (18.5%)	359 (20.2%)	
50-59 years	409 (20.9%)	405 (22.8%)	
60-69 years	336 (17.2%)	267 (15.0%)	
70-79 years	210 (10.7%)	149 (8.4%)	
80+ years	90 (4.6%)	72 (4.1%)	
Gender			0.823
Female	576 (29.4%)	517 (29.1%)	
Male	1380 (70.6%)	1262 (70.9%)	
ВМІ			
Mean (SD)	28.8 (6.3)	29.6 (7.4)	0.074
Median [IQR]	28.0 [24.4-32.1]	28.7 [24.7-32.9]	
Non-urological comorbidities			0.075
Yes	538 (36.2%)	453 (32.9%)	
No	950 (63.8%)	923 (67.1%)	
Urological comorbidities			0.662
Yes	56 (3.8%)	46 (3.4%)	
No	1429 (96.2%)	1309 (96.6%)	
Ureteric stone location?			0.52
Left	1014 (51.8%)	929 (52.2%)	
Right	873 (44.6%)	799 (44.9%)	
Bilateral	69 (3.53%)	51 (2.87%)	
Maximum stone size (mm)			0.687
≤5	1026 (57.5%)	926 (56.9%)	
6-10	633 (35.5%)	598 (36.8%)	
11-19	108 (6.1%)	85 (5.2%)	
≥20	18 (1.0%)	17 (1.1%)	
Active infection at time of presentation			0.032
Yes	258 (13.2%)	193 (10.8%)	
No	1697 (86.8%)	1586 (89.2%)	
Fever (Temperature >38 degree C) at any stage in index admission			0.031
Yes	151 (9.3%)	107 (7.1%)	
No	1482 (90.8%)	1406 (92.9%)	
Admission blood tests CRP (mg/L)			0.562
Mean (SD)	27.7 (64.6)	26.4 (68.7)	
Median [IQR]	4.0 [1.0-17.0]	3.0 [1.0-13.0]	
Admission blood tests WCC (x10^9/L)			0.725

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	p- value
Mean (SD)	11.0 (6.2)	11.0 (4.2)	
Median [IQR]	10.3 [8.1-12.9]	10.7 [8.1-13.1]	
Positive blood culture			0.749
Yes	51 (38.1%)	41 (41.0%)	
No	83 (61.9%)	59 (59.0%)	
Positive urine culture (>10^5 cfu)			0.796
Yes	97 (21.8%)	78 (20.9%)	
No	347 (78.2%)	296 (79.1%)	
Admission blood tests Creatinine (umol/L)			0.765
Mean (SD)	105 (70.8)	106 (75.9)	
Median [IQR]	94.0 [77.0-113.0]	93.0 [78.0-113.0]	
AKI			0.041
Yes	340 (21.9%)	290 (18.9%)	
No	1211 (78.1%)	1245 (81.1%)	
AKI Grade (KGIDO)			
Grade 1	226 (74.1%)	202 (74.8%)	
Grade 2	55 (18.0%)	44 (16.3%)	
Grade 3	24 (7.9%)	24 (8.9%)	

Table 1: baseline characteristics between the pre-pandemic patient cohort and the pandemic patient cohort. AKI = acute kidney injury CFU = colony forming units; CRP = C reactive protein; IQR = interquartile range; SD = standard deviation; WCC = white cell count.

	Pre-pandemic period	Pandemic period	P-value
	(N=1956)	(N=1779)	r-value
Admitted to hospital?			<0.001
Yes	1057 (54.0%)	827 (46.5%)	
No	899 (46.0%)	952 (53.5%)	
Length of stay (days)			0.021
Mean (SD)	4.08 (8.04)	3.29 (5.94)	
Alpha blocker			<0.001
Yes	316 (17.4%)	414 (25.4%)	
No	1501 (82.6%)	1219 (74.6%)	
Antibiotics			
Yes-Oral	171 (8.74%)	148 (8.32%)	0.251
Yes-IV	304 (15.5%)	245 (13.8%)	
No	1481 (75.7%)	1386 (77.9%)	
Interventional management			0.295
Yes	787 (40.2%)	685 (38.5%)	
No	1169 (59.8%)	1094 (61.5%)	
	Pre-pandemic period	Pandemic period	
	(N=787)	(N=685)	P-value
Anaesthetic			<0.001
General	390 (92.2%)	173 (76.2%)	
Non-general	33 (7.80%)	54 (23.8%)	
ESWL for index stone			<0.001
Yes	179 (22.7%)	233 (34.1%)	
No	608 (77.3%)	451 (65.9%)	

Ureteroscopy for index stone				
Yes	450 (57.2%)	325 (47.5%)		
No	337 (42.8%)	359 (52.5%)		
Stent insertion for index stone (alone or as	part of Ureteroscopy)		<0.001	
Yes	538 (68.4%)	374 (54.6%)		
No	249 (31.6%)	311 (45.4%)		
Emergency nephrostomy insertion for inde	x stone		0.027	
Yes	56 (7.1%)	72 (10.5%)		
No	731 (92.9%)	613 (89.5%)		
Operative complication			0.616	
Yes	87 (11.5%)	68 (10.5%)		
No	671 (88.5%)	580 (89.5%)		
30-day highest Clavien-Dindo grade				
None	671 (88.5%)	580 (89.5%)		
1	44 (5.8%)	28 (4.3%)		
II	29 (3.8%)	15 (2.3%)		
III-A	1 (0.1%)	8 (1.2%)		
III-B	9 (1.2%)	12 (1.9%)		
IV-A	2 (0.3%)	0 (0.0%)		
IV-B	1 (0.1%)	2 (0.3%)		
V (death)	1 (0.1%)	3 (0.5%)		

Table 2: Management and complications

	Pre-pandemic period	Pandemic period	P-value	
	(N=1956)	(N=1779)		
Primary treatme	ent success		0.113	
Yes	1379 (73.8%)	1308 (76.1%)		
No	490 (26.2%)	410 (23.9%)		
Unplanned read	lmission for urete	ric stone disease	0.826	
Mean (SD)	0.173 (0.520)	0.176 (0.500)		
Creatinine (umo	ol/L)		0.305	
Mean (SD)	87.3 (36.9)	89.4 (51.9)		
CKD			0.989	
Yes	230 (17.2%)	213 (17.1%)		
No	1111 (82.8%)	1036 (82.9%)		
Death			0.014	
Yes	40 (2.14%)	18 (1.05%)		
No	1830 (97.9%)	1700 (99.0%)		
Additional inter	ventions			
ESWL			0.231	
Yes	87 (4.9%)	95 (5.8%)		
No	1689 (95.1%)	1519 (94.1%)		
Ureteroscopy +	0.072			
Yes	358 (19.5%)	288 (17.1%)		
No	1481 (80.5%)	1400 (82.9%)		
Stent insertion		0.62		
Yes	84 (4.8%)	69 (4.3%)		

No

1685 (95.3%)

1524 (95.7%)

Nephrostomy in	sertion		0.782
Yes	17 (1.0%)	13 (0.8%)	
No	1767 (99.0%)	1602 (99.2%)	

- Table 3: Outcomes and additional operative management required at 6 months
- 372 follow-up.

SUPPLEMENTARY TABLES

373

374

375

	Pre-pandemic period	Pandemic period	P-value
	(N=787)	(N=685)	P-value
ASA grade			
1. A normal healthy patient	219 (42.0%)	134 (43.4%)	0.498
2. A patient with mild systemic disease	199 (38.1%)	125 (40.5%)	
3. A patient with severe systemic disease	89 (17.0%)	45 (14.6%)	
4. A patient with severe systemic disease that is a	15 (2.87%)	5 (1.62%)	
constant threat to life	13 (2.07 /0)	3 (1.0270)	
WHO/ECOG Performance status			
Fully active, able to carry on all pre-disease activities	326 (73.1%)	211 (75.9%)	0.214
Restricted in physical strenuous activity, able to perform	87 (19.5%)	39 (14.0%)	
light work	. (,		
Ambulatory and capable of all self-care, unable to work	18 (4.04%)	15 (5.40%)	
Capable of limited self-care only	11 (2.47%)	7 (2.52%)	
Completely disabled. Confined to bed or chair	4 (0.897%)	6 (2.16%)	

Table S1: ASA Grade and WHO/ECOG Performance status